Author for correspondence: Juntian Liu, Department of Pharmacology, Xi’an Jiaotong University School of Medicine, Xi’an, Shaanxi 710061, China (fax +86 29 82655188, e-mail [email protected]).

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Abstract: Huperzine A is an anticholinesterase and cognitive enhancer, which is able to alleviate the symptoms of memory dysfunction in the mouse. The fast metabolization rate and narrow therapeutic spectrum makes it unfit for clinical use. Poly(lactic-co-glycolic acid) microsphere as delivery system effectively maintains the blood concentration of huperzine A by a slow-release effect over a long time. In the present article, we investigated the prolonged protective effect of microsphere-containing huperzine A on memory dysfunction induced by scopolamine. Spectrophotometric assay was used to determine the activity of acetylcholinesterase (AChE) and passive avoidance tests to evaluate memory performance. The results show that a bolus dose of microsphere-containing huperzine A (at a dose of 300 µg/kg or 600 µg/kg) administered intramuscularly can effectively maintain drug activity and significantly decrease the activity of AChE from day 3 to 14, the strongest effect seen on day 3 and 7. Accompanying the reduction of the activity of AChE, microsphere-containing huperzine A (300 µg/kg or 600 µg/kg) remarkably increased transfer latency time and no transfer response on the second trial through mitigating the memory impairments induced by scopolamine as compared to the scopolamine model group. Microsphere-containing huperzine A showed cognitive enhancing properties and anticholinesterase activity and may thus be a candidate for treatment of memory impairment.

References

1 Blockland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res 1996; 21: 285–300.
10.1016/0165-0173(95)00016-X
Google Scholar
2 Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
10.1016/S0140-6736(76)91936-X
CAS PubMed Web of Science® Google Scholar
3 Davis KL, Yamamura HI. Cholinergic underactivity in human memory disorders. Life Sci 1978; 23: 1729–34.
10.1016/0024-3205(78)90100-5
CAS PubMed Web of Science® Google Scholar
4 Hagan JJ, Jansen JHM, Broekkamp CLE. Blockade of spatial learning by the M₁ muscarinic antagonist pirenzepine. Psychopharmacology 1987; 93: 470–6.
10.1007/BF00207237
CAS PubMed Web of Science® Google Scholar
5 Giacobini E. New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors? Prog Brain Res 1996; 109: 311–23.
10.1016/S0079-6123(08)62114-7
CAS PubMed Web of Science® Google Scholar
6 Shafferman A, Kronman C, Flashner Y et al. Mutagenesis of human acetylcholinesterase Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem 1992; 267: 640–8.
10.1016/S0021-9258(19)37091-7
Google Scholar
7 Tang XC, HanYF. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drugs Review 1999; 5: 281–300.
10.1111/j.1527-3458.1999.tb00105.x
CAS Google Scholar
8 Baker RW. Controlled Release of Biologically Active Agents. Wiley, New York, 1987.
Google Scholar
9 Chasin M, Langer R. Biodegradable Polymers as Drug Delivery Systems. Drugs and the Pharmaceutical Sciences. Marcel Dekker, New York, 1990; 45.
Google Scholar
10 Benita S. Microencapsulation: Methods and Industrial Applications. Drugs and the Pharmaceutical Sciences. Marcel Dekker, New York, 1996; 73.
Google Scholar
11 Washington C. Drug release from microparticulate systems. In: S Benita (eds). Microencapsulation: Methods and Industrial Applications. Drugs and the Pharmaceutical Sciences. Marcel Dekker, New York, 1996; 155–81.
Web of Science® Google Scholar
12 Brioni JD, Hock FJ, McGaugh JJ. Drug effects on learning and memory. In: GH Vogel, WH Vogel (eds). Drug Discovery and Evaluation: Pharmacological Assays. Springer, New York, 1997; 335–6.
Google Scholar
13 Moral-naranjo MT, Cabezas-herrera J, Vidal CJ. Molecular forms of acetyl- and butyrylcholinesterases in normal and dystrophic mouse brain. J Neurosci Res 1996; 43: 224–34.
10.1002/(SICI)1097-4547(19960115)43:2<224::AID-JNR10>3.0.CO;2-6
CAS PubMed Web of Science® Google Scholar
14 Lowry OH, Rosebrough NJ, Farr AI, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 265–75.
10.1016/S0021-9258(19)52451-6
CAS PubMed Web of Science® Google Scholar
15 Fibiger HC. Central cholinergic systems and memory. In: LR Squire, E Lindenlaub (eds). The Biology of Memory. Symposia Medica Hoechst. Springer-Verlag, New York, 1990; 23.
Google Scholar
16 Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction: a critical review. Science 1982; 217: 408–17.
10.1126/science.7046051
CAS PubMed Web of Science® Google Scholar
17 Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy of Alzheimer's disease. Prog Brain Res 1993; 98: 431–8.
10.1016/S0079-6123(08)62429-2
CAS PubMed Web of Science® Google Scholar
18 Siddiqui MF, Levey AI. Cholinergic therapies in Alzheimer's disease. Drugs Future 1999; 24: 417–44.
10.1358/dof.1999.024.04.668318
CAS Google Scholar
19 Bartus JD, Johnson HR. Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol Biochem Behav 1976; 5: 39–46.
10.1016/0091-3057(76)90286-0
CAS PubMed Web of Science® Google Scholar
20 Sitaram N, Weingartner H, Gillin JC. Human serial learning: enhancement with arecholine and choline impairment with scopolamine. Science 1978; 211: 274–6.
10.1126/science.351808
Web of Science® Google Scholar
21 Amitava D, Girja S, Chandishwar N, Raghwendra P, Satyawan S, Hemant KS. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 2002; 73: 893–900.
10.1016/S0091-3057(02)00940-1
PubMed Web of Science® Google Scholar
22 Cory B, Martin K, Amanda C, Kyekyoon K, Daniel WP. Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release 2002; 82: 137–47.
10.1016/S0168-3659(02)00136-0
PubMed Web of Science® Google Scholar
23 Chu DF, Fu XQ, Liu WH, Liu K, Li YX. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm 2006; 325: 116–23.
10.1016/j.ijpharm.2006.06.032
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume100, Issue3

March 2007

Pages 190-195

Prolonged Effects of Poly(lactic-co-glycolic acid) Microsphere-Containing Huperzine A on Mouse Memory Dysfunction Induced by Scopolamine

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley